Abstract:
Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.
Abstract:
Disclosed are methods for treating disorders associated with dopamine receptor activity. In some embodiments, the disclosed methods include assaying the nucleic acid from a subject for the genotype of the variable number tandem repeats (VNTR) polymorphism in the dopamine transporter DAT1/SLC6A3 gene, wherein when one or two alleles for 9 tandem repeats is detected a dopamine partial agonist is administered to the subject; and wherein when two alleles for 10 tandem repeats is detected a dopamine modulator is not administered to the subject. Also provided are methods for treating disorders associated with dopamine receptor activity that include genotyping a subject with respect to a COMT polymorphism, a DRD2 polymorphism, a 48-base-pair VNTR polymorphism in DRD4 exon 3, and/or a ANKK1 TaqA1 polymorphism, and methods for detecting susceptibility to dopamine modulator therapy for conditions associated with dopamine receptor activity.
Abstract:
A compound, or a pharmaceutically acceptable salt thereof, having a structure of wherein Z is aryl or substituted aryl, heteroaryl, or substituted heteroaryl; X is —S—, —S(O)—, or S(O)2—; R20 and R21 are each independently H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, or halogenated alkyl; one of R22, R23, and R24 is —O— and the others of R22, R23 and R24 are independently —CH2—, or —C(R13)— wherein R13 is alkyl, alkenyl, alkynyl, trialkylsilyl group, or —(CH2)mOR15, wherein R15 is alkyl or an aryl and m is an integer in the range of 1 to 10; and R25 is H, alkyl, substituted alkyl, halogen, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, C1-C3 alkoxy, aryloxy, or —(CH2)qOR17, wherein R17 is alkyl an aryl and q is an integer in the range of 1 to 10.
Abstract:
A catheter including a plurality of balloons extending from the outer surface of the catheter that when inflated create a seal between the catheter and the patient's thereby eliminating leakage of fluids from around catheter during the procedure.
Abstract:
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of degenerative diseases and disorders.
Abstract:
Disclosed are systems, compositions, and methods for three-dimensional (3D) printing. An example system includes a plurality dispensers configured to deposit materials from their tips and a printing surface for receiving the materials. The system includes a position sensing detector configured to detect positions of the tips of the dispensers and the location and dimensions of the printing surface. The system includes a robotic positioning device configured to drive the dispensers. The system also includes a control unit configured to receive and map in a 3D space the positions of the tips of the dispensers and the position and dimensions of the printing surface. The control unit is further configured to control the robotic positioning device to drive the dispensers relative to the printing surface in the 3D space, and to independently deposit materials on the printing surface, or on material deposited on the printing surface.
Abstract:
A composition comprising a plurality of cell aggregates for use in the production of engineered organotypic tissue by organ printing. A method of making a plurality of cell aggregates comprises centrifuging a cell suspension to form a pellet, extruding the pellet through an orifice, and cutting the extruded pellet into pieces. Apparatus for making cell aggregates comprises an extrusion system and a cutting system. In a method of organ printing, a plurality of cell aggregates are embedded in a polymeric or gel matrix and allowed to fuse to form a desired three-dimensional tissue structure. An intermediate product comprises at least one layer of matrix and a plurality of cell aggregates embedded therein in a predetermined pattern. Modeling methods predict the structural evolution of fusing cell aggregates for combinations of cell type, matrix, and embedding patterns to enable selection of organ printing processes parameters for use in producing an engineered tissue having a desired three-dimensional structure.
Abstract:
Rib hook devices, systems, and methods of assembling and using the devices and systems are disclosed. The rib hook device includes a body with a first end and a second end and a rod attachment member coupled to and extending away from the second end of the body. The rib hook system includes at least one rib hook device, a first rod for engaging the at least one rib hook device, and at least one fastener for securing the first rod to the at least one rib hook device. Methods for assembling and using the rib hook devices and systems are also disclosed.
Abstract:
Provided are peptides that can inhibit collagen synthesis, processing and/or secretion from scar forming cells or fibroblasts. Also provided are methods for using the peptides to produce an anti-fibrotic, anti-scarring, anti-inflammatory, and/or pro-regenerative effect, e.g., on an injured or diseased tissue.